14 terminated. 14 Phase 2, 4 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Terminated 14 |
| Phase 3 | 4 | Terminated 4 |
| Phase 1 | 3 | Terminated 3 |
Follow Metaplasia: new trials by email Literature Review of Metaplasia trials Research Report on Metaplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy Lucentis® (Raibizumab) double-dose, Lucentis® (Raibizumab) regular-dose - Polypoidal Choroidal Vasculopathy | Phase 2 / Phase 3 | Terminated | Sun Yat-sen University | 5 | 2018-08-01 | 2019-09-19 |
| Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) ICON-1, aflibercept - Choroidal Neovascularization, Wet Macular Degeneration | Phase 2 | Terminated | Iconic Therapeutics, Inc. | 15 | 2018-03-26 | 2021-04-13 |
| Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization Aflibercept - Corneal Neovascularization | Phase 1 / Phase 2 | Terminated | Rabin Medical Center | 6 | 2017-03-02 | 2019-09-16 |
| Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD Fovista® (anti-PDGF BB) plus anti-VEGF - Age-related Macular Degeneration | Phase 2 | Terminated | Ophthotech Corporation | 101 | 2014-07-01 | 2024-02-23 |
| Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab ranibizumab - Age-Related Macular Degeneration | Phase 2 / Phase 3 | Terminated | University of California, San Diego | 20 | 2011-07-01 | 2019-08-28 |
| Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD STAKEL - Macular Degeneration, Choroidal Neovascularization | Phase 2 | Terminated | Steba Biotech S.A. | 10 | 2010-06-01 | 2018-09-17 |
| Topical IL-1-Ra for Treatment of Corneal Neovascularization Placebo, IL-1Ra - Corneal Neovascularization | Phase 1 / Phase 2 | Terminated | Reza Dana, MD | 10 | 2009-04-01 | 2017-05-08 |
| The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration Everolimus, Ranibizumab - Choroidal Neo-Vascular Age-onset Macular Degeneration, Age-related Macular Degeneration | Phase 2 | Terminated | Novartis Pharmaceuticals | 16 | 2009-02-01 | 2011-08-19 |
| Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration Sirolimus in combination with ranibizumab, Placebo in combination with ranibizumab - Age-Related Macular Degeneration, Choroidal Neovascularization | Phase 2 | Terminated | Santen Inc. | 62 | 2008-12-01 | 2013-01-10 |
| Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration Sirolimus - Age-related Macular Degeneration, Choroidal Neovascularization | Phase 1 / Phase 2 | Terminated | Santen Inc. | 20 | 2008-09-01 | 2013-01-10 |
| Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD TG100801 - Macular Degeneration, Choroidal Neovascularization | Phase 2 | Terminated | TargeGen | 7 | 2007-07-01 | 2010-03-29 |
| Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) Verteporfin Photodynamic Therapy, Ranibizumab, Placebo - Macular Degeneration, Choroidal Neovascularization | Phase 2 / Phase 3 | Terminated | Novartis | 255 | 2007-05-01 | 2011-04-21 |
| A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration AGN 211745, Ranibizumab 500µg - Choroid Neovascularization, Age-Related Macular Degeneration | Phase 2 | Terminated | Allergan | 138 | 2007-01-01 | 2015-09-07 |
| Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment Intravitreal Bevacizumab - Diabetic Proliferative Retinopathy, Vascular Vein Oclussion | Phase 2 / Phase 3 | Terminated | Asociación para Evitar la Ceguera en México | 2005-12-01 | 2024-06-03 |
Choroidal Neovascularization (11) · Macular Degeneration (9) · Corneal Neovascularization (2) · Polypoidal Choroidal Vasculopathy (1) · Wet Macular Degeneration (1)
Eye Diseases (14) · Neovascularization, Pathologic (14) · Pathologic Processes (14) · Pathological Conditions, Signs and Symptoms (14) · Choroid Diseases (12) · Uveal Diseases (12) · Retinal Degeneration (10) · Retinal Diseases (10) · Corneal Diseases (2) · Choroidal Neovascularization (1) · Macular Degeneration (1)
Ranibizumab (6) · Sirolimus (2) · aflibercept (2) · 4-chloro-3-(5-methyl-3-((4-(2-pyrrolidin-1-ylethoxy)phenyl)amino)-1,2,4-benzotriazin-7-yl)phenol (1) · Everolimus (1) · Interleukin 1 Receptor Antagonist Protein (1) · Verteporfin (1) · padeliporfin (1)
Santen Inc. (2) · Allergan (1) · Asociación para Evitar la Ceguera en México (1) · Iconic Therapeutics, Inc. (1) · Novartis (1) · Novartis Pharmaceuticals (1) · Ophthotech Corporation (1) · Rabin Medical Center (1) · Reza Dana, MD (1) · Steba Biotech S.A. (1) · Sun Yat-sen University (1) · TargeGen (1) · University of California, San Diego (1)
United States (10) · France (2) · United Kingdom (2) · Australia (1) · Austria (1) · Belgium (1) · China (1) · Denmark (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Netherlands (1) · Philippines (1) · Poland (1)
Joel Naor, MD (2) · Adrienne Scott, Doctor (1) · Francine Behar Cohen, Professor (1) · Gabriela Burian, MD (1) · Henry Ferreyra, MD (1) · Irit Bahar, MD (1) · John Wells, Professor (1) · Lin Lu, MD, phD (1) · Neil Bressler, Professor (1) · Peter Kaiser, M.D. (1) · Reza Dana, MD, MPH, MSc (1)
PMID 14557174, PMID 16897221, PMID 19549103, PMID 19726427, PMID 19936307, PMID 20136420, PMID 22424834, PMID 22426346, PMID 23352196, PMID 25079064, PMID 25646029, PMID 26114826, PMID 27020759, PMID 27124775